Pharmaceutical research response

Pharmaceutical research response

In the fight against the pandemic, Derby-based Bondholder N4 Pharma Plc is undertaking a Covid-19 proof of concept research project for Nuvec®, a novel delivery system for cancer treatments and vaccines.

The company has received delivery of an initial quantity of the Covid-19 plasmid DNA from the National Institute for Health in the USA and has appointed Evotec International Gmbh to undertake the proof of concept work for use with Covid-19 at its site in Toulouse, France.

Nigel Theobald, Chief Executive Officer, commented: “The initial proof of concept data package for Nuvec® using Covid-19 is expected to last approximately six months and is a key priority for the Company to demonstrate the versatility and potential for our Nuvec® delivery system, and to license Nuvec® to partners looking to develop vaccines for this virus."

Back to news